Article abstract


Nature Medicine 14, 1333 - 1342 (2008)
Published online: 23 November 2008 | doi:10.1038/nm.1891



There is a Corrigendum (January 2009) associated with this Article.

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

Rihab Nasr1,7,8, Marie-Claude Guillemin1,8, Omar Ferhi1, Hassan Soilihi1, Laurent Peres1, Caroline Berthier1, Philippe Rousselot2, Macarena Robledo-Sarmiento1, Valérie Lallemand-Breitenbach1, Bernard Gourmel1, Dominique Vitoux1, Pier Paolo Pandolfi3, Cécile Rochette-Egly4, Jun Zhu1,5 & Hugues de Thé1,5,6


Retinoic acid and arsenic trioxide target the protein stability and transcriptional repression activity of the fusion oncoprotein PML-RARA, resulting in regression of acute promyelocytic leukemia (APL). Phenotypically, retinoic acid induces differentiation of APL cells. Here we show that retinoic acid also triggers growth arrest of leukemia-initiating cells (LICs) ex vivo and their clearance in PML-RARA mouse APL in vivo. Retinoic acid treatment of mouse APLs expressing the fusion protein PLZF-RARA triggers full differentiation, but not LIC loss or disease remission, establishing that differentiation and LIC loss can be uncoupled. Although retinoic acid and arsenic synergize to clear LICs through cooperative PML-RARA degradation, this combination does not enhance differentiation. A cyclic AMP (cAMP)-dependent phosphorylation site in PML-RARA is crucial for retinoic acid–induced PML-RARA degradation and LIC clearance. Moreover, activation of cAMP signaling enhances LIC loss by retinoic acid, identifying cAMP as another potential APL therapy. Thus, whereas transcriptional activation of PML-RARA is likely to control differentiation, its catabolism triggers LIC eradication and long-term remission of mouse APL. Therapy-triggered degradation of oncoproteins could be a general strategy to eradicate cancer stem cells.

Top
  1. Université de Paris 7/CNRS UMR 7151, Equipe labellisée N°11 Ligue Nationale Contre le Cancer, Service de Biochimie, Hôpital St. Louis, 1, Av. C. Vellefaux, 75475 Paris CEDEX 10, France.
  2. UFR de Médecine Université de Paris 5 & Hematology, Hôpital Mignot, 177 rue de Versailles, 78157 Le Chesnay, France.
  3. Department of Pathology, Beth Israel Deaconess Medical Center, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA.
  4. Institut de Génétique et de Biologie Moléculaire et Cellulaire, Department of Functional Genomics, 1 rue Laurent Fries, BP 10142, Illkirch F-67400, France.
  5. CNRS laboratoire associé MPC, Shanghai Institute of Hematology, Rui Jin Hospital, 197 Rui Jin Road, 200025 Shanghai, China.
  6. Institut Universitaire de France.
  7. Current address: Department of Internal Medicine, American University of Beirut, Bliss Street, P.O. Box 11-0236, Beirut, Lebanon.
  8. These authors contributed equally to this work.

Correspondence to: Hugues de Thé1,5,6 e-mail: dethe@univ-paris-diderot.fr